The present invention relates to antigen binding molecules (ABMs). Inparticular embodiments, the present invention relates to recombinantmonoclonal antibodies, including chimeric, primatized or humanized antibodiesspecific for human EGFR. In addition, the present invention relates to nucleicacid molecules encoding such ABMs, and vectors and host cells comprising suchnucleic acid molecules. The invention further relates to methods for producingthe ABMs of the invention, and to methods of using these ABMs in treatment ofdisease. In addition, the present invention relates to ABMs with modifiedglycosylation having improved therapeutic properties, including antibodieswith increased Fc receptor binding and increased effector function.
